This balance is disturbed by the prevalence of angiogenic factors in cancer, such as the vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and chemokines, which led to the concept of the ‘angiogenic switch’ [7,8,9]. This evidence concerns the gene FGF2 and cancer.